Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2015-08-28 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
2015年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "山东瑞康医药股份有限公司 2015 年半年度报告全文" which translates to "Shandong Realcan Pharmaceutical Co., Ltd. 2015 Semi-Annual Report Full Text." It contains detailed financial data, including revenue, net profit, cash flow, and segment analysis for the first half of 2015 (January 1 to June 30, 2015). The document includes sections such as company overview, financial data and indicators summary, board report, business analysis, investment status, and fundraising usage. The length is substantial (15,000 characters), and it contains actual financial statements and substantive financial data and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). It is not a mere announcement or certification, but a full report with detailed financial and operational information for the half-year period. Therefore, the correct classification is IR with high confidence. H1 2015
2015-08-28 Chinese
2015年第三次临时股东大会的律师见证法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the witnessing of the 2015 third extraordinary general meeting (临时股东大会) of Shandong Ruikang Pharmaceutical Co., Ltd. It details the legal compliance of the meeting's convening, attendance, agenda, voting procedures, and results. The document does not contain financial statements or performance data but focuses on the legality and procedural correctness of the shareholders' meeting and its resolutions. This type of document is typically classified as a Declaration of Voting Results & Voting Rights Announcements (DVA) because it confirms the voting outcomes and legal validity of the shareholder meeting decisions.
2015-08-26 Chinese
2015年第三次临时股东大会决议的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the resolutions passed at the 2015 third extraordinary general meeting of shareholders of Shandong Ruikang Pharmaceutical Co., Ltd. It details the meeting date, attendance, voting results on specific proposals related to issuance of medium-term notes and short-term financing bonds, and includes a legal opinion confirming the validity of the meeting and voting process. The document does not contain financial statements or detailed financial analysis but reports the official voting results of shareholder decisions. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (1672 characters), consistent with a voting results announcement rather than a full report or presentation.
2015-08-26 Chinese
关于筹划非公开发行股票停牌进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Shandong Ruikang Pharmaceutical Co., Ltd. regarding the progress of a non-public stock issuance plan and the continuation of stock trading suspension. It details multiple prior announcements about the suspension and progress updates related to the non-public issuance of shares. The document does not contain financial statements or detailed financial data but is an update on capital raising activities and stock suspension status. This fits the category of Capital/Financing Update (CAP). The document length is short and focused on the financing event, not a full report or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2015-08-25 Chinese
关于筹划非公开发行股票停牌进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Shandong Ruikang Pharmaceutical Co., Ltd. regarding the progress of a non-public stock issuance plan and the related trading suspension (停牌) of the company's shares. It details the dates of previous announcements about the trading suspension and states that the suspension will continue to protect investors and avoid stock price volatility. The document is short (1194 characters) and focuses on the update about the capital raising process (non-public stock issuance) and trading suspension progress. It does not contain financial statements, audit information, or detailed financial data. It is clearly an update on financing activities and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2015-08-18 Chinese
关于筹划非公开发行股票停牌进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Shandong Ruikang Pharmaceutical Co., Ltd. regarding the progress of a non-public stock issuance plan and the related trading suspension of its shares. It details the dates of previous suspension announcements and states that the stock will continue to be suspended to protect investors and prevent abnormal price fluctuations. The document is short (1139 characters) and serves as an update on the capital raising process, specifically about the non-public issuance of shares and trading suspension progress. It does not contain financial statements or detailed financial data, nor is it a full report or presentation. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2015-08-11 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.